Antitumor immunity. II. Viability, tumorigenicity, and immunogenicity of neuraminidase-treated tumor cells: effective immunization of animals with a tumor vaccine.
A dimethylbenzdithionaphthene (DBDN)-induced fibrosarcoma showed reduced transplantability if previously treated with Vibrio cholerae neuraminidase (VCN). However, the reduced transplantability of VCN-treated tumor cells was not associated with any loss of their viability or tumorigenic capability, but appeared to be due to their increase in immunogenicity. High doses of VCN-treated tumor cells could grow even in normal individuals. Lower doses, which did not induce tumor development in normal individuals, did so if injected into immunosuppressed animals. Although X-irradiation of VCN-treated tumor cells reduced their tumorigenic potential, it did not impair their increased immunogenic properties. Thus a suitable method for the preparation of a "tumor vaccine" was provided. The immunization of animals with the vaccine and a working hypothesis regarding its mechanism of action were described.
D000818:Animals; D000951:Antigens, Neoplasm; D002273:Carcinogens; D002470:Cell Survival / Q000187:drug effects; D005354:Fibrosarcoma / Q000139:chemically induced / Q000276:immunology*; D006854:Hydrocortisone / Q000494:pharmacology; D007114:Immunization; D007165:Immunosuppression Therapy; D051379:Mice; D009281:Naphthalenes; D011830:Radiation Effects; D012513:Sarcoma, Experimental / Q000276:immunology
D000951:Antigens, Neoplasm; D002273:Carcinogens; D009281:Naphthalenes; D006854:Hydrocortisone